{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T21:35:17Z","timestamp":1783632917494,"version":"3.55.0"},"reference-count":22,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Thyroid\u00ae"],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Lenvatinib, a multikinase inhibitor, is for progressive radioiodine-refractory-differentiated thyroid cancer (RR-DTC) patients. However, there are a lot of drug-related adverse events (AEs) that can affect the quality of life (QoL) of patients. The aims of this study were (a) to evaluate, and compared with other series, the safety of lenvatinib used in RR-DTC patients enrolled in an Italian expanded access program (EAP), and (b) to evaluate their QoL during treatment with lenvatinib.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>To evaluate the safety, we recorded and graded all AEs during the 6 months of lenvatinib treatment in 39 RR-DTC patients. We compared the safety profile of lenvatinib observed in our patients with that reported in the study of (E7080) levatinib in differentiated cancer of the thyroid (SELECT) and tumeurs thyroidiennes refractaires (TUTHYREF) network studies. Moreover, we evaluated the QoL in our series by using the European Organization for Research and Treatment (EORTC) Quality of Life Questionnaire-Core 30 and the pain visual analogue scale (VAS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The most frequent AEs among our 39 RR-DTC patients were hypertension (80.5%), fatigue (58.3%), diarrhea (36.1%), stomatitis (33.3%), hand\/foot syndrome (33.3%), and weight loss (30.5%). The most prevalent grade 3\/4 AE was hypertension (25%). When compared with previous studies (i.e., SELECT and TUTHYREF), a significantly lower percentage of our patients experienced diarrhea, nausea, proteinuria, and weight loss. No statistically significant differences in the QoL of our patients evaluated before, during, and at the end of follow-up (6 months after starting the therapy) were found. However, a slight improvement of the general health and emotional and cognitive status associated with a slightly worsening of physical role and social functioning was observed during these 6 months. Pain, dyspnea, insomnia, and constipation moved toward better values, while fatigue, nausea and vomiting, appetite loss, and diarrhea worsened. By comparing the pain VAS, an overall reduction of the level of pain was found.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>The safety profile of the drug was similar to that already reported with some differences in the prevalence and severity of the AEs. Regarding the QoL, the EAP showed a trend of improvement of the global health status and a reduction of symptoms correlated to the disease. The clinical impact of fatigue, anorexia\/weight loss and stomatitis, mainly due to the drug itself, continues to represent the major issue in the management of these patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/thy.2020.0276","type":"journal-article","created":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T04:48:31Z","timestamp":1599713311000},"page":"224-232","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":39,"title":["Safety and Quality-of-Life Data from an Italian Expanded Access Program of Lenvatinib for Treatment of Thyroid Cancer"],"prefix":"10.1177","volume":"31","author":[{"given":"Carlotta","family":"Giani","sequence":"first","affiliation":[{"name":"Endocrinology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Valerio","sequence":"additional","affiliation":[{"name":"Endocrinology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Bongiovanni","sequence":"additional","affiliation":[{"name":"Osteoncology and Rare Tumors Center Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRST, IRCCS, Meldola, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cosimo","family":"Durante","sequence":"additional","affiliation":[{"name":"Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Grani","sequence":"additional","affiliation":[{"name":"Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toni","family":"Ibrahim","sequence":"additional","affiliation":[{"name":"Osteoncology and Rare Tumors Center Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRST, IRCCS, Meldola, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Mariotti","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Massa","sequence":"additional","affiliation":[{"name":"Department of Medical Science, Fondazione IRCCS Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiana","family":"Pani","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Pellegriti","sequence":"additional","affiliation":[{"name":"Endocrinology Division, Garibaldy Nesima Hospital, Catania, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso","family":"Porcelli","sequence":"additional","affiliation":[{"name":"Department of Public Health, University of Naples \u201cFederico II,\u201d Naples, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Salvatore","sequence":"additional","affiliation":[{"name":"Department of Public Health, University of Naples \u201cFederico II,\u201d Naples, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Tavarelli","sequence":"additional","affiliation":[{"name":"Endocrinology Division, Garibaldy Nesima Hospital, Catania, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Torlontano","sequence":"additional","affiliation":[{"name":"Department of Medical Science, Fondazione IRCCS Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Locati","sequence":"additional","affiliation":[{"name":"Head and Neck Cancer Medical Oncology Unit, Fondazione IRCCS \u201cIstituto Nazionale dei Tumori,\u201d Milan, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Molinaro","sequence":"additional","affiliation":[{"name":"Endocrinology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Elisei","sequence":"additional","affiliation":[{"name":"Endocrinology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2021,2,12]]},"reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30172-6"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-2838"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.2217\/fon.15.68"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2017.02.009"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.23131"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2017.06.001"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1406470"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2017.0205"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2019.05.031"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-19-0763"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2019.0221"},{"key":"e_1_3_5_13_2","unstructured":"US Department of Health and Human Services: Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. https:\/\/www.eortc.be\/services\/doc\/ctc\/CTCAE_4.03_2010-06 14_QuickReference_5x7.pdf"},{"key":"e_1_3_5_14_2","unstructured":"Fayers PM Aaronson NK Bjordal K Groenvold M Curran D Bottomley A on behalf of the EORTC Quality of Life Group. 2001. EORTC QLQ-C30 Scoring ManualQuality of Life EORTC Data Center. Third edition. European Organisation for Research and Treatment of Cancer Brussels."},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0039-6109(05)70381-9"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00422219"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.10.002"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-18-0049"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.4158\/EP171822.OR"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijchp.2017.11.002"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.09.029"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-5106-y"}],"container-title":["Thyroid\u00ae"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/thy.2020.0276","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/thy.2020.0276","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/thy.2020.0276","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T22:07:32Z","timestamp":1777586852000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/thy.2020.0276"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["10.1089\/thy.2020.0276"],"URL":"https:\/\/doi.org\/10.1089\/thy.2020.0276","relation":{},"ISSN":["1050-7256","1557-9077"],"issn-type":[{"value":"1050-7256","type":"print"},{"value":"1557-9077","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2]]}}}